Prevalence of musculoskeletal pain and statin use

Journal of General Internal Medicine

Volumn 23, Issue 8, 2008, Pages 1182-1186

  Buettner, Catherine ^a,c   Davis, Roger B ^a,b,c   Leveille, Suzanne G ^a,c   Mittleman, Murray A ^a,b,c   Mukamal, Kenneth J ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Hydroxymethylglutaryl coa reductase inhibitors; Musculoskeletal pain; Statin myopathy

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BLOOD PRESSURE; BODY HEIGHT; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; PREVALENCE; QUESTIONNAIRE;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUSCULOSKELETAL PAIN; NUTRITION SURVEYS; PREVALENCE; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES;

EID: 49649091314     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-008-0636-7     Document Type: Article

References (25)

1. M Mitka 2003 Expanding statin use to help more at-risk patients is causing financial heartburn JAMA 290 17 2243 2245
2. CP Cannon BA Steinberg SA Murphy JL Mega E Braunwald 2006 Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 3 438 445
3. GC Fonarow KE Watson 2003 Effective strategies for long-term statin use Am J Cardiol 92 1A 27i 34i
4. DM Black 2002 A general assessment of the safety of HMG CoA reductase inhibitors (statins) Curr Atheroscler Rep 4 1 34 41
5. FM Sacks 2002 Adherence to statin therapy: why aren't we doing better? Am J Med 113 8 685 686
6. PD Thompson PM Clarkson RS Rosenson 2006 An assessment of statin safety by muscle experts Am J Cardiol 97 8A 69C 76C
7. JM McKenney MH Davidson TA Jacobson JR Guyton 2006 Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 97 8A 89C 94C
8. RC Pasternak SC Smith Jr. CN Bairey-Merz SM Grundy JI Cleeman C Lenfant 2002 ACC/AHA/NHLBI clinical advisory on the use and safety of statins J Am Coll Cardiol 40 3 567 572
9. J Armitage 2007 The safety of statins in clinical practice Lancet 370 9601 1781 1790
10. PR de Sauvage Nolting RJ Buirma BA Hutten JJ Kastelein 2002 Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies with Familial Hypercholesterolemia [ExPRESS FH]) Am J Cardiol 90 2 181 184
11. E Bruckert G Hayem S Dejager C Yau B Begaud 2005 Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study Cardiovasc Drugs Ther 19 6 403 414
12. S Franc S Dejager E Bruckert M Chauvenet P Giral G Turpin 2003 A comprehensive description of muscle symptoms associated with lipid-lowering drugs Cardiovasc Drugs Ther 17 5-6 459 465
13. National Center for Health Statistics, National Health and Nutrition Examination Survey Institutional Review Board Approval. (Accessed April 18, 2007, at http://www.cdc.gov/nchs/about/major/nhanes/intro_mec.htm ).
14. A Kashani CO Phillips JM Foody 2006 Risks associated with statin therapy: a systematic overview of randomized clinical trials Circulation 114 25 2788 2797
15. JW Jukema AV Bruschke AJ van Boven 1995 Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) Circulation 91 10 2528 2540
16. DB Hunninghake EA Stein CA Dujovne 1993 The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia N Engl J Med 328 17 1213 1219
17. M Davidson P Ma EA Stein 2002 Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia Am J Cardiol 89 3 268 275
18. B Kerzner J Corbelli S Sharp 2003 Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia Am J Cardiol 91 4 418 424
19. MRC/BHF 2002 Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 9326 7 22
20. DH Blankenhorn SP Azen DM Kramsch 1993 Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS) Ann Intern Med 119 10 969 976
21. KA Antons CD Williams SK Baker PS Phillips 2006 Clinical perspectives of statin-induced rhabdomyolysis Am J Med 119 5 400 409
22. PD Thompson P Clarkson RH Karas 2003 Statin-associated myopathy JAMA 289 13 1681 1690
23. J Oh MR Ban BA Miskie RL Pollex RA Hegele 2007 Genetic determinants of statin intolerance Lipids in Health and Disease 6 7
24. GD Vladutiu Z Simmons PJ Isackson 2006 Genetic risk factors associated with lipid-lowering drug-induced myopathies Muscle Nerve 34 2 153 162
25. H Sinzinger J O'Grady 2004 Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems Br J Clin Pharmacol 57 4 525 528